- Home
- MMA vs BLRX Comparison
MMA vs BLRX Comparison
Compare MMA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMA
- BLRX
- Stock Information
- Founded
- MMA 2013
- BLRX 2003
- Country
- MMA Australia
- BLRX Israel
- Employees
- MMA N/A
- BLRX N/A
- Industry
- MMA
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MMA
- BLRX Health Care
- Exchange
- MMA Nasdaq
- BLRX Nasdaq
- Market Cap
- MMA 16.3M
- BLRX 15.3M
- IPO Year
- MMA 2024
- BLRX 2011
- Fundamental
- Price
- MMA $1.33
- BLRX $4.70
- Analyst Decision
- MMA
- BLRX Strong Buy
- Analyst Count
- MMA 0
- BLRX 2
- Target Price
- MMA N/A
- BLRX $19.00
- AVG Volume (30 Days)
- MMA 757.5K
- BLRX 77.4K
- Earning Date
- MMA 01-21-2025
- BLRX 08-14-2025
- Dividend Yield
- MMA N/A
- BLRX N/A
- EPS Growth
- MMA N/A
- BLRX N/A
- EPS
- MMA N/A
- BLRX N/A
- Revenue
- MMA $407,412.00
- BLRX $22,340,000.00
- Revenue This Year
- MMA N/A
- BLRX N/A
- Revenue Next Year
- MMA N/A
- BLRX N/A
- P/E Ratio
- MMA N/A
- BLRX N/A
- Revenue Growth
- MMA N/A
- BLRX 91.68
- 52 Week Low
- MMA $0.60
- BLRX $2.30
- 52 Week High
- MMA $4.11
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- MMA N/A
- BLRX 57.56
- Support Level
- MMA N/A
- BLRX $4.05
- Resistance Level
- MMA N/A
- BLRX $4.64
- Average True Range (ATR)
- MMA 0.00
- BLRX 0.38
- MACD
- MMA 0.00
- BLRX -0.01
- Stochastic Oscillator
- MMA 0.00
- BLRX 86.17
About MMA Alta Global Group Limited
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.